Molecular Insight Pharmaceuticals has hired Daniel Peters, the former president of GE Healthcare, as its new president and CEO.
Avila Therapeutics has tapped Katrine Bosley as its new CEO.
Altair Therapeutics has named Joel Martin, Ph.D., as its President and CEO.
Gen-Probe announced that Carl W. Hull has formally succeeded the company's long-time leader, Henry L. Nordhoff, as CEO.
InVasc has named William D. Johnston, Ph.D. as CEO and a member of the board of directors. Dr. Johnston will succeed Bobby V. Khan, M.D., Ph.D., a founder of InVasc.
Simcere Pharmaceutical Group named Dr. Peng Wang as chief scientific officer.
Orthovita announced that Nancy C. Broadbent will join the company as senior vice president and CFO.
ConjuChem Biotechnologies says that Lennie Ryer, vice president and CFO, has left the company.
Fate Therapeutics has hired Pratik Multani, M.D., M.S., as vice president of clinical development.
SkyePharma PLC has named a new non-executive director, Dr Thomas Werner, to the board.
Watson Pharmaceuticals has promoted Patricia Eisenhaur as its new vice president of investor relations and corporate communications.
VasoGenix Pharmaceuticals named heart failure/heart transplant cardiologist James Young, M.D., to its board of directors.
Emisphere Technologies announced that Franklin M. Berger, CFA, has been appointed to its board of directors.
Spherix has elected a new, independent director, Thomas Peter, to begin serving immediately.
AltheaDx announced the appointment of Dr. Greg Tsongalis to their Scientific Advisory Board.